Results 241 to 250 of about 792,761 (305)

Macrophage Membrane‐Cloaked, ROS‐Triggered Quercetin Nanocarriers Target Ovarian Lesions to Treat Polycystic Ovary Syndrome

Advanced Healthcare Materials, EarlyView.
The synthesis process of MM@PCD@QNPs and its potential mechanism for treating PCOS. (A) Assembly steps of MM@PCD@QNPs. (B) Synthesis and decomposition of MM@PCD@QNPs. (C) Potential therapeutic mechanisms of MM@PCD@QNPs for PCOS. PCD, PABP conjugated with DEX polymer; QUR, quercetin; CDI, N, N′‐carbonyldiimidazole; DEX, dextran; PABP, 4‐(hydroxymethyl ...
Wenzhu Li, Yu Guan, Nan Song, Feng Zhang, Zhimin Deng, Tailang Yin, Yanbing Yang, João Conde, Wenyi Jin, Zhinang Yin   +9 more
wiley   +1 more source

Etiology of Iridocorneal Endothelial Syndrome: Viral Infection and Immune Suppression. [PDF]

Cornea
Zhang J, Yuan B, Peng R, Zhang P, Liu X, Qu Y, Xiao G, Li Y, Zhang X, Hong J.   +9 more
europepmc   +1 more source

Aptamer‐Based Delivery Systems for VEGF and NGF Modulation in Ocular Therapies

Advanced Healthcare Materials, EarlyView.
Aptamer‐based delivery systems targeting NGF and VEGF hold significant potential for precise and sustained treatment of complex diseases affecting both the anterior and posterior segments of the eye. This review critically summarizes current strategies for NGF and VEGF delivery as well as VEGF sequestration, providing a clinical perspective on how ...
Nadine Best, Gizem Karabiyik, Gerd Geerling, Sarah Barbara Zwingelberg, Gregor Lang, Martin Humenik   +5 more
wiley   +1 more source

Metal-Supramolecular Drug Delivery System Empowered Meningeal Lymphatic Vessels-Bridged Intracranial-Peripheral Dual Immune Modulation for Reversing Glioblastoma Immune Suppression. [PDF]

Adv Sci (Weinh)
Zhang C, Xu Z, Xu X, Zhang Z, Luo R, Ren P, Luo Y, Wu Q, Liu X, Liu G, He X, Liu Y.   +11 more
europepmc   +1 more source

S100A9 enhances tumor immune suppression and cancer cell survival in small cell lung cancer. [PDF]

Cell Death Dis
Charan M, Mishra S, Shilo K, Zhang X, Verma AK, Ghanta P, Webb A, Ganju RK.   +7 more
europepmc   +1 more source

Oncogenic KRAS mutations drive immune suppression through immune-related regulatory network and metabolic reprogramming. [PDF]

Cell Death Dis
Tian L, Li H, Cui H, Tang C, Zhao P, Wang X, Cheng Y.   +6 more
europepmc   +1 more source

Prevention of secondary infections by interferon-gamma in ICU-acquired sustained immune suppression in France: study protocol of the PLATINIUM randomised trial. [PDF]

BMJ Open
Hernandez Padilla AC, Daix T, Hotchkiss RS, Monneret G, Tadie JM, Jeannet R, Plateker O, Vaidie J, Durand-Zaleski I, Magne J, Giraudeau B, François B.   +11 more
europepmc   +1 more source

Integrative multi-omic analysis identified <i>ERBB2</i> mutations and senescence-driven immune suppression as dual therapeutic targets in LAR triple-negative breast cancer. [PDF]

Cancer Biol Med
Zhao Y, Wang H, Wang Y, Jiang Y, Hu X, Shao Z.   +5 more
europepmc   +1 more source

Modeling the pre-metastatic niche of gastric cancer peritoneal metastasis under spatiotemporal resolution and investigating EVs-mediated immune suppression. [PDF]

Front Immunol
Zhang X, Zhang C, Zhang Z, Zhang X, Wang K.   +4 more
europepmc   +1 more source

Correction to: FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas. [PDF]

J Natl Cancer Inst
europepmc   +1 more source